和邦生物(603077.SH):子公司擬投設合夥企業 以投資10GW超高效單晶太陽能硅片項目
格隆匯10月18日丨和邦生物(603077.SH)公佈,公司控股子公司四川武駿光能股份有限公司(“武駿光能”)擬與佟興雪、海南省仁愛文化中心(有限合夥)(“海南仁愛”)、天津昊鼎新能源合夥企業(有限合夥)(“天津昊鼎”)共同投資設立安徽阜興晶體科技有限公司,主營業務為生產光伏發電用硅片,投資總額30億元,首期註冊資本為4.55億元,全部為現金出資。其中,武駿光能出資3.41億元,獲得58.33%股權。
阜興科技擬投資10GW超高效單晶太陽能硅片項目,投資總額30億元。該項目生產模式主要是採用高純太陽能級硅材料,通過晶體生長、切片等製成工藝,生產出硅片。項目達產後預計年銷售收入65億元,年利潤總額11.7119億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.